NeuroPace, Inc. Stock

Equities

NPCE

US6412881053

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 16:00:00 2024-04-26 EDT 5-day change 1st Jan Change
13.39 USD +3.08% Intraday chart for NeuroPace, Inc. -4.22% +29.87%
Sales 2024 * 75.21M 103M Sales 2025 * 88.44M 121M Capitalization 385M 526M
Net income 2024 * -32M -43.74M Net income 2025 * -27M -36.91M EV / Sales 2024 * 5.43 x
Net Debt 2024 * 23.62M 32.29M Net Debt 2025 * 44.42M 60.72M EV / Sales 2025 * 4.85 x
P/E ratio 2024 *
-11.5 x
P/E ratio 2025 *
-13.9 x
Employees 171
Yield 2024 *
-
Yield 2025 *
-
Free-Float 80.52%
More Fundamentals * Assessed data
Dynamic Chart
1 day+3.08%
1 week-4.22%
Current month+1.44%
1 month-1.76%
3 months-8.10%
6 months+113.90%
Current year+29.87%
More quotes
1 week
12.94
Extreme 12.94
14.51
1 month
12.10
Extreme 12.1
15.77
Current year
9.50
Extreme 9.5001
18.15
1 year
3.80
Extreme 3.8
18.15
3 years
1.22
Extreme 1.22
26.97
5 years
1.22
Extreme 1.22
27.38
10 years
1.22
Extreme 1.22
27.38
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 23-07-09
Founder 63 97-11-18
Founder 82 97-11-30
Members of the board TitleAgeSince
Director/Board Member 52 21-10-31
Director/Board Member 68 97-11-18
Founder 82 97-11-30
More insiders
Date Price Change Volume
24-04-26 13.39 +3.08% 69,086
24-04-25 12.99 -4.20% 32,096
24-04-24 13.56 -3.21% 44,430
24-04-23 14.01 +0.07% 152,876
24-04-22 14 +0.14% 126,312

Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm

More quotes
NeuroPace, Inc. is a medical device company. The Company is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The Company has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorder.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
13.39 USD
Average target price
17.71 USD
Spread / Average Target
+32.29%
Consensus